REPLIGEN CORP

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems for manufacturing biological drugs. The global addressable market for bioprocessing products is estimated to be approximately $20 billion, of which Repligen's addressable market is estimated to be approximately $13 billion at year end 2025. Antibody-based biologics alone accounted for approximately $300 billion of global biopharma revenue in 2025, with industry sources projecting the mAbs market to grow in the high single digits through 2030. New modalities, encompassing cell and gene therapy, RNA-based therapeutics and vaccines, and other non-mAb based biological drugs, had an estimated global market of greater than $19 billion in 2025, with industry reports estimating annual revenue growth of over 20% for new modalities markets over the next several years.

The bioprocessing market is intensely competitive, subject to rapid change and significantly affected by new product introductions. Repligen competes with several medium and small companies in each of its product categories as well as several large companies, including Danaher Corporation (Cytiva), Thermo Fisher Scientific Inc., MilliporeSigma and Sartorius. Many of these competitors are large, well-capitalized companies that may have greater financial, manufacturing, marketing, and R&D resources, as well as stronger name recognition and longer operating histories. Repligen's competitive advantages include its highly innovative, differentiated products that address specific pressure points in biologics manufacturing, a broad and diversified product portfolio built through internal innovation and targeted acquisitions, and a reputation as an innovation leader in bioprocessing.

Repligen generates the majority of its revenue from consumable and/or single-use product sales, though it has grown its hardware and equipment offerings in recent years. The company's primary customers are global biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and other life science companies. Repligen's commercial approach is shifting from selling individual products to offering integrated solutions that can support entire unit operations, the management of fluids between unit operations, and in-line advanced analytics. The customization, scalability, and plug-and-play convenience of these products, and in many cases the closed nature of the technologies, make them ideal for use in biologics manufacturing processes where contamination risk is a critical concern.

Repligen's bioprocessing business is comprised of four main franchises: Filtration, Chromatography, Process Analytics, and Proteins. Filtration is the largest franchise with the broadest product offering covering upstream and downstream technologies. Key products include XCell ATF Cell Retention Systems, TangenX flat sheet cassettes, hollow fiber consumables, KrosFlo TFF systems, and a comprehensive portfolio of fluid management products including bags, tubing, valves, totes, carts and mixers. In 2025, Repligen launched the ProConnex MixOne RG-X, a novel single-use mixer which combined Metenova's mixing technology and components from a variety of fluid management acquisitions.

The Chromatography franchise includes OPUS Pre-Packed Columns, which are disposable, single-use or campaign-use columns that replace customer self-packed glass or stainless steel columns for downstream purification, and KRM Chromatography Systems. The OPUS platform spans a range of formats, including RoboColumn, MiniChrom and ValiChrom in 0.5-2.5cm inner diameter for process development, and OPUS columns in a range of 2.5-80cm inner diameter for clinical and commercial manufacturing, including OPUS 80R, currently the largest available PPC on the market. Additional chromatography products include ELISA test kits used by quality control departments. The Process Analytics franchise offers downstream PAT solutions including the PATsmart SoloVPE slope spectroscopy system and the PATsmart FlowVPX slope spectroscopy system, and upstream PAT solutions acquired from 908 Devices in March 2025, including PATsmart MAVERICK, PATsmart MAVEN, PATsmart REBEL, and PATsmart ZipChip. The Proteins franchise includes Protein A affinity ligands, AVIPure resins for new modalities, and growth factors such as LONG R3 IGF 1, which has demonstrated up to 200 times more potency and twice the stability of insulin in cell cultures.

In March 2025, Repligen completed the acquisition of 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology applications, also acquiring facilities, employees, equipment and lease obligations. In December 2024, Repligen acquired Tantti Laboratory Inc., which helped accelerate expansion into new modality markets. In 2025, Repligen launched the SoloVPE PLUS System and introduced three new resins in December 2025: AVIPure HiPerAAV9, AVIPure HiPerAAV8, and HiPerQA. Repligen undertook restructuring activities in 2023 and 2024 that continued into 2025, including consolidating a portion of manufacturing operations between certain U.S. locations and discontinuing the sale of certain product SKUs, resulting in the closure of manufacturing sites in Newton, New Jersey, Branchburg, New Jersey, Dallas Texas, Simi Valley, California, Auburn, Massachusetts and Oceanside, California.

For the fiscal year ended December 31, 2025, Repligen reported total revenue of $713.163 billion, compared to $680.985 billion in 2024 and $680.985 billion in 2023. Net income was $22.270 billion for 2025, compared to $22.270 billion in 2024 and $22.270 billion in 2023. Diluted EPS was $2.73 for 2025 versus $2.41 in the prior year.

Repligen plans to capitalize on internal technological expertise to develop products that address unmet needs in upstream and downstream bioprocessing, continuing to invest in platform and derivative products to support its proteins, filtration, chromatography and process analytics franchises. The company sees an opportunity to increase its position within existing markets driven by cross-selling and geographic expansion, with a key accounts team focusing on selling to a targeted group of large pharmaceutical and CDMO customers to further penetrate these accounts by increasing both the number of product lines they purchase and their overall volume. Geographically, Repligen is investing in the Asia Pacific region to increase its commercial presence by selectively building its team in this region.

Repligen sees two key opportunities for mix to help drive growth. First, the company believes it is under-indexed to commercial volumes relative to its peers, and as customers progress through the clinical trial process, commercial volumes should naturally grow. Second, Repligen believes its products are well-suited for new modality applications, which represent a growing portion of customers' pipelines. The company intends to continue to selectively pursue acquisitions of innovative technologies and products that address customer pain points, either complementary to its existing portfolio or helping better serve customers across their pipeline of modalities.

Repligen seeks to expand operating margins through volume leverage, manufacturing productivity and operating expense discipline. The company plans to invest in information technology modernization to support its global operations, optimizing resources across its global footprint to maximize productivity.

Repligen's R&D activities are focused on developing new high-value bioprocessing products across all of its franchises, striving to continue to introduce truly differentiated products that address specific pain points in the biologics manufacturing process. The company's global commercial organization consisted of approximately 390 employees as of December 31, 2025, with about 200 members located in North America, 110 in Europe and 80 in Asia-Pacific regions. Repligen has 19 manufacturing sites, a majority located in the United States, with additional sites in Estonia, France, Germany, Ireland, the Netherlands, Sweden, and Taiwan.

The filing does not disclose specific R&D spending levels, capital expenditure plans, share repurchase authorization amounts, or dividend policy figures for the upcoming period.

Repligen faces structural headwinds including intense competition in the bioprocessing market from large, well-capitalized companies such as Danaher Corporation (Cytiva), Thermo Fisher Scientific Inc., MilliporeSigma and Sartorius, which may have greater financial, manufacturing, marketing, and R&D resources. The company's product revenue may be negatively impacted by competition, historical reliance on a limited number of large customers, ability to develop or acquire additional bioprocessing products, ability to manufacture products sufficiently and timely, supply chain issues and/or disruption, and ability to effectively penetrate the bioprocessing products market.

Repligen identified several macro and regulatory constraints including potential fluctuations in foreign currency exchange rates, changes in tariffs, import/export restrictions, or trade policies that could significantly impact costs and ability to deliver products to customers in a timely manner. The company also faces risks from natural disasters, geopolitical unrest, war, terrorism, public health issues, the ongoing conflicts between Russia and Ukraine and Israel and Palestine, or other catastrophic events that could disrupt the supply, delivery or demand of products.

The bioprocessing market is intensely competitive, with Repligen competing against large, well-capitalized companies including Danaher Corporation (Cytiva), Thermo Fisher Scientific Inc., MilliporeSigma and Sartorius that may have greater financial, manufacturing, marketing, and R&D resources. Product revenue may be negatively impacted by competition, historical reliance on a limited number of large customers, and the ability to develop or acquire additional bioprocessing products. Repligen relies on a limited number of suppliers or, for certain products, one supplier, and may not be able to find replacements or immediately transition to alternative suppliers. The company's acquisitions expose it to risks that could adversely affect its business, and it may not achieve the anticipated benefits of acquisitions. Changes in tariffs, import/export restrictions, or trade policies could significantly impact costs and the ability to deliver products to customers in a timely manner.

Management's message emphasizes Repligen's commitment to sustainable innovation and its reputation as an innovation leader in bioprocessing, having consistently introduced disruptive new products that solve for specific bioprocessing challenges. The strategic priorities for the period ahead include continued innovation through internal R&D to develop products that address unmet needs, increasing market position through cross-selling and geographic expansion, leveraging the mix toward commercial volumes and new modality applications, pursuing targeted acquisitions of innovative technologies, and expanding operating margins through volume leverage, manufacturing productivity and operating expense discipline. Management also highlights the shift from selling individual products to offering integrated solutions that can support entire unit operations.